Identification of isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell-based high-throughput screening

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Hill, Jeff W ^a   Thompson, Jeffrey F ^a   Carter, Mark B ^a   Edwards, Bruce S ^a   Sklar, Larry A ^a   Rosenberg, Gary A ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPHENESIN CARBAMATE; ISOXSUPRINE; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN REGION; CEREBROVASCULAR ACCIDENT; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HIGH THROUGHPUT SCREENING; NERVE CELL; NEUROPROTECTION; NONHUMAN; PERIPHERAL VASCULAR DISEASE; RAT; REOXYGENATION; RIGHT HEMISPHERE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; MALE; SPONTANEOUSLY HYPERTENSIVE RAT; SPRAGUE DAWLEY RAT; STROKE;

ANIMALS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; ISOXSUPRINE; MALE; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; STROKE;

EID: 84900529324     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096761     Document Type: Article

References (21)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2013) American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 127: e6-e245.
2. Eissa A, Krass I, Bajorek BV (2012) Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA). J Clin Pharm Ther 37: 620-9.
3. Chong CR, Sullivan DJ Jr (2007) New uses for old drugs. Nature 448: 645-6. (Pubitemid 47236844)
4. Allison M (2012) NCATS launches drug repurposing program. Nat Biotechnol 30: 571-2.
5. Wang JK, Portbury S, Thomas MB, Barney S, Ricca DJ, et al. (2006) Cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform. Proc Natl Acad Sci U S A 103: 10461-6. (Pubitemid 44051189)
6. Beraki S, Litrus L, Soriano L, Monbureau M, To LK, et al. (2013) A pharmacological screening approach for discovery of neuroprotective compounds in ischemic stroke. PLoS One 8: e69233.
7. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R (2006) Statistical practice in high-throughput screening data analysis. Nat Biotechnol 24: 167-75. (Pubitemid 43221699)
8. Hill JW, Poddar R, Thompson JF, Rosenberg GA, Yang Y (2012) Intranuclear matrix metalloproteinases promote DNA damage and apoptosis induced by oxygen-glucose deprivation in neurons. Neuroscience 220: 277-90.
9. Semkova I, Schilling M, Henrich-Noack P, Rami A, Krieglstein J (1996) Clenbuterol protects mouse cerebral cortex and rat hippocampus from ischemic damage and attenuates glutamate neurotoxicity in cultured hippocampal neurons by induction of NGF. Brain Res 717: 44-54. (Pubitemid 26153435)
10. Culmsee C, Semkova I, Krieglstein J (1999) NGF mediates the neuroprotective effect of the beta2-adrenoceptor agonist clenbuterol in vitro and in vivo: evidence from an NGF-antisense study. Neurochem Int 35: 47-57. (Pubitemid 29251228)
11. Junker V, Becker A, Hühne R, Zembatov M, Ravati A, et al. (2002) Stimulation of beta-adrenoceptors activates astrocytes and provides neuroprotection. Eur J Pharmacol 446: 25-36. (Pubitemid 34722554)
12. Culmsee C, Junker V, Kremers W, Thal S, Plesnila N, et al. (2004) Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol. Stroke 35: 1197-202. (Pubitemid 38543543)
13. Gogas KR (2006) Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 6: 68-74.
14. Lish PM, Hillyard IW, Dungan KW (1960) The uterine relaxant properties of isoxsuprine. J Pharmacol Exp Ther. 1960;129:438-44.
15. Beart PM, Mercer LD, Jarrott B (1991) [125I]Ifenprodil: a convenient radioligand for binding and autoradiographic studies of the polyamine-sensitive site of the NMDA receptor. Neurosci Lett 124: 187-9.
16. Elliott J, Soydan J (1995) Characterisation of beta-adrenoceptors in equine digital veins: implications of the modes of vasodilatory action of isoxsuprine. Equine Vet J Suppl 19: 101-7.
17. Belloli C, Carcano R, Arioli F, Beretta C (2000) Affinity of isoxsuprine for adrenoreceptors in equine digital artery and implications for vasodilatory action. Equine Vet J 32: 119-24.
18. Hussain SM, Gedye JL, Naylor R, Brown AL (1976) The objective measurement of mental performance in cerebrovascular disease. A double-blind controlled study, using a graded-release preparation of isoxsuprine. Practitioner 216: 222-8.
19. Briones-Garduño JC, González-Alvarez R (1997) Isoxsuprine in hypertension during pregnancy. Gac Med Mex 133: 403-6.
20. Wesseling H, Wouda AA (1975) Effects of intravenously administered isoxsuprine in patients with Raynaud's phenomenon. Vasa 4: 168-74.
21. Giorgino FL, Egan CG (2010) Use of isoxsuprine hydrochloride as a tocolytic agent in the treatment of preterm labour: a systematic review of previous literature. Arzneimittelforschung 60: 415-20.